This monthly report outlines key developments in China’s antitrust sector for July. SAMR Solicits Public Comments on the Revised Provisions on the Prohibition of Monopoly Agreements, Refining the “Safe Harbor” Standards for...more
7/21/2025
/ Administrative Agencies ,
Antitrust Provisions ,
China ,
Competition ,
Compliance ,
Enforcement Actions ,
Merger Controls ,
Mergers ,
Monopolization ,
New Legislation ,
Popular ,
Regulatory Reform ,
Regulatory Requirements ,
Safe Harbors ,
State Administration for Market Regulation (SAMR) ,
Unfair Competition
This monthly report outlines key developments in China’s antitrust sector for June. The following events merit special attention: SAMR Seeks Comments on Provisions for Curbing Acts of Abusing Administrative Power to Eliminate...more
6/20/2025
/ Administrative Authority ,
Anti-Monopoly ,
Antitrust Provisions ,
Application Programming Interface (APIs) ,
Bid Rigging ,
China ,
Collusion ,
Competition ,
Competition Authorities ,
Enforcement ,
Enforcement Actions ,
Government Agencies ,
Monopolization ,
NDRC ,
New Legislation ,
Penalties ,
Personal Liability ,
Pharmaceutical Industry ,
Price-Fixing ,
Proposed Legislation ,
Proposed Rules ,
State Administration for Market Regulation (SAMR) ,
Supply Chain ,
Supply Shortages ,
Supreme Peoples Court ,
Unfair Competition ,
Water Supplies
This monthly report outlines key developments in China’s antitrust sector for May. The following events merit special attention...more
5/28/2025
/ Abuse of Power ,
Acquisition Agreements ,
Anti-Competitive ,
Anti-Monopoly ,
Antitrust Investigations ,
Antitrust Provisions ,
Antitrust Violations ,
China ,
Competition ,
DuPont ,
Enforcement Actions ,
Merger Agreements ,
Merger Controls ,
Monopolization ,
Popular ,
State Administration for Market Regulation (SAMR)
On May 9, 2025, the Tianjin Municipal Administration for Market Regulation (“Tianjin AMR”) announced administrative penalties against four manufacturers of dexamethasone sodium phosphate (“DSP”) active pharmaceutical...more
5/27/2025
/ Anti-Monopoly ,
Antitrust Provisions ,
Antitrust Violations ,
Cartels ,
China ,
Competition ,
Coronavirus/COVID-19 ,
Corporate Governance ,
Enforcement Actions ,
Healthcare ,
Life Sciences ,
Monopolization ,
Penalties ,
Pharmaceutical Industry ,
Popular ,
Price-Fixing ,
Regulatory Oversight ,
Sanctions
This monthly report outlines key developments in China’s antitrust sector for April. The following events merit special attention...more
4/17/2025
/ Abuse of Dominance ,
Acquisition Agreements ,
Antitrust Provisions ,
China ,
Competition ,
Corporate Sales Transactions ,
Enforcement Actions ,
Government Agencies ,
Hong Kong ,
Merger Agreements ,
Merger Controls ,
Monopolization ,
New Guidance ,
Penalties ,
Pharmaceutical Industry ,
State Administration for Market Regulation (SAMR)